Wechselwirkungen · Reyataz
REYATAZ 50 mg oral powder · Abschnitt 4.5 · PDF-Seite 60
HOS-112204 · Präparat HOS-093615
The mechanism of interaction is CYP3A4 and UGT1A1 inhibition. Concentrations of atazanavir (when given with ritonavir) were not significantly affected. Methadone, stable No significant effect on methadone No dosage adjustment is maintenance dose concentrations was observed. Given that necessary if methadone is co- (atazanavir 400 mg once daily) low dose ritonavir (100 mg twice daily) has administered with REYATAZ. been shown to have no significant effect on methadone concentrations, no interaction is expected if methadone is co-administered with REYATAZ, based on these data. PULMONARY ARTERIAL HYPERTENSION PDE5 Inhibitors Sildenafil Co-administration with REYATAZ may A safe and effective dose in result in increased concentrations of the combination with REYATAZ PDE5 inhibitor and an increase in PDE5- has not been established for inhibitor-associated adverse events. sildenafil when used to treat pulmonary arterial The mechanism of interaction is CYP3A4 hypertension. Sildenafil, when inhibition by atazanavir and/or ritonavir. used for the treatment of pulmonary arterial hypertension, is contraindicated (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): methadone (HOS-086198) sildenafil (HOS-086162) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage b18d066e48bffe433295d60679cd4c3927cb2c9e30e4f13b4dcdeb50ae5a39f4 · Zeichen 74413–76443 im Abschnitt